

**Amendments to the Specification**

On page 4, at line 21 through page 5, line 3, please amend the specification as follows.

--The inhibiting step may be carried out by downregulating EMAP II expression in the subject by an amount effective to stimulate vascular growth in the lungs of the subject. Compounds useful for downregulating EMAP II expression are, in general, antisense oligonucleotides that bind to EMAP II mRNA and disrupt translation thereof, or oligonucleotides that bind to EMAP II DNA and disrupt transcription thereof. Such oligonucleotides may be natural or synthetic (such as described in U.S. Patent No. 5,665,593 to Kole, the disclosure of which is incorporated by reference herein in its entirety), and are typically at least 4, 6 or 8 nucleotides in length, up to the full length of the corresponding DNA or mRNA. Such oligonucleotides are selected to bind to the DNA or mRNA by Watson-Crick pairing based on the known sequence of the ~~EMAP II~~ EMAP II DNA as described in U.S. Patent No. 5,641,867 to Stern et al., the disclosure of which is incorporated by reference herein in its entirety. For example, an antisense oligonucleotide of the invention may consist of a 4, 6 or 8 or more nucleotide oligonucleotide having a base sequence corresponding to the EMAP II DNA sequence (SEQ ID NO:2) disclosed in Stern et al., *supra*, up to 20, 30, or 40 nucleotides in length, or even the full length of the mRNA/DNA sequence coding for EMAP II (SEQ ID NOS:3 and 4) disclosed in Stern et al., *supra*. In addition, such compounds may be identified in accordance with known techniques as described below. --

Please enter the attached Substitute Sequence Listing at the end of the specification.

Attachment: Substitute Sequence Listing